Botanix Pharma
2015
FOUNDED
PUBLIC
STATUS
1-10
EMPLOYEES
BOT
STOCK SYMBOL
$0.06
SHARE PRICE
(As of Friday Closing)
Description
Botanix Pharmaceuticals Ltd is a clinical stage cannabinoid therapeutics company. The company focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne.
Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
ASX
Primary Office
- PO Box 1407
- Subiaco, Western Australia 6904
- Australia
+61 (08) 0000 0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Botanix Pharma’s full profile, request a free trial.
Botanix Pharma Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $0.05 - $0.20 | $44.7M | $0.06 | 2.59M | 774M |
Botanix Pharma Financials Summary
|
In Thousands,
USD |
TTM
31-Dec-2019
|
FY 2019
30-Jun-2019
|
FY 2018
30-Jun-2018
|
FY 2017
30-Jun-2017
|
|---|---|---|---|---|
| Enterprise Value | 41,140 | 85,950 | 42,134 | 13,550 |
| EBITDA | (12,264) | (8,596) | (3,630) | |
| Net Income | (12,183) | (8,530) | (3,597) | |
| Total Assets | 3,642 | 13,010 | 4,540 | |
| Total Debt | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Botanix Pharma Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Botanix Pharma‘s full profile, request access.
Request full access to PitchBook